October 10, 2006 04:44 PM Eastern Time
OAK BROOK, Ill.--(BUSINESS WIRE)--In connection with the
launch of its new website, Invirion Diagnostics, LLC today
announced the release of its newest reagent kit: ViroTect
HCV In-Cell Detection Kit. This kit is intended for researchers
in the health sciences who are studying cells infected
with the hepatitis C virus (HCV). The kit is based on
the company’s proprietary technology for labeling
specific viral RNA’s inside cells. Since viruses
typically live inside cells, Invirion’s assays provide
a unique and powerful method for studying viral replication
in the cells that they infect and for determining if active
viral replication is or is not inhibited by the drugs
that are used to treat disease caused by the virus.
Hepatitis C (HCV) infection constitutes a universal healthcare
problem. Indeed, it is the leading cause of end stage
liver disease, a significant risk factor for the development
of hepatocellular carcinoma, and is the leading cause
of liver transplant enlistment. In the United States roughly
seven million people are chronically infected. Unfortunately,
only a fraction of patients respond to the current anti-viral
therapy and, perhaps more disturbingly, patients thought
to have cleared the virus are frequently found to harbor
detectable levels of viral message within a new extrahepatic
cellular compartment, the peripheral blood leukocytes.
The Invirion ViroTect HCV assay is intended for use by
researchers to detect HCV RNA in cells from individuals
infected with HCV or in cell lines infected with HCV.
The assay will provide new insights into the pathology
of the disease and into the efficacies of the drugs that
are being developed to treat hepatitis C.
Invirion also makes kits for the monitoring of HIV replication
in cells and the detection of HPV E6, E7 mRNA for cervical
cancer screening.
Invirion Diagnostics, LLC is the first theranostics company
dedicated to the detection, monitoring and treatment of
life-threatening viral diseases such as hepatitis C, HIV/AIDS,
cervical cancer, and organ transplant rejection. Invirion
was founded in 1999 with the goal of commercializing state-of-the-art
molecular virology technology to make a difference in
people’s lives. Invirion’s research, development,
and commercialization efforts are focused on monitoring
viruses that cause human disease and using the information
gleaned from these novel assays to develop therapeutic
products that rationally target the viral lifecycle. For
more information on the company, its technology and its
products, please visit the Invirion’s website at
www.invirion.com.
|
|
|
|
